SCHEDULE: Lilly Endowment Holds 9.6% Stake in Eli Lilly

Lilly Endowment, Inc. has reported a continued beneficial ownership of 9.6% of Eli Lilly and Company's common stock as of September 30, 2026.

Summary

• Lilly Endowment, Inc. has filed an amendment to its Schedule 13G, reporting its beneficial ownership of Eli Lilly and Company's common stock.
• As of September 30, 2026, Lilly Endowment, Inc. beneficially owns 90,066,978 shares of Eli Lilly's common stock.
• This ownership represents 9.6% of the total outstanding shares.
• The filing indicates sole voting power and sole dispositive power over these shares.
• The percentage is based on 941,357,065 shares outstanding as of June 30, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a stable, significant ownership stake by a major endowment fund without immediate indications of aggressive buying or selling.

Positives

• Lilly Endowment, Inc. maintains a substantial and stable ownership position in Eli Lilly and Company.
• The endowment fund has sole voting and dispositive power, indicating clear control over its significant stake.

Negatives

• No new information suggesting a change in strategy or a significant shift in ownership is presented.

Risks

• Concentration risk for Lilly Endowment, Inc. due to a significant portion of its holdings being in a single company.
• Potential for future changes in ownership by Lilly Endowment, Inc. which could impact Eli Lilly's stock price.

Future Outlook

The filing itself does not contain forward-looking statements or guidance regarding Eli Lilly and Company's future performance. It solely reports the current ownership status of Lilly Endowment, Inc.

Management Comments

• The filing is a certification by Lilly Endowment, Inc. stating that to the best of its knowledge and belief, the information set forth is true, complete, and correct.

Industry Context

StockSavvy.ai notes that large endowment funds often hold significant, long-term positions in major pharmaceutical companies like Eli Lilly, reflecting confidence in the sector and the specific company's prospects.

Stakeholder Impact

• Shareholders: The stable, significant ownership by Lilly Endowment, Inc. can be viewed as a positive signal of long-term support, potentially contributing to stock price stability.

Next Steps

• Lilly Endowment, Inc. will continue to monitor its investment in Eli Lilly and Company.
• Future amendments to Schedule 13G will be filed if ownership levels change significantly.

Key Dates

Keywords

Eli Lilly, Lilly Endowment, Schedule 13G, Beneficial Ownership, Common Stock, Ownership Stake, Investment Holding